CSTI-500 is under clinical development by ConSynance Therapeutics and currently in Phase I for Prader-Willi Syndrome (PWS). According to GlobalData, Phase I drugs for Prader-Willi Syndrome (PWS) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CSTI-500’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CSTI-500 overview
CSTI-500 (BMS-866949) is under development for the treatment of hyperphagia in Prader-Willi syndrome and for hypothalamic obesity (HO). The drug candidate is administered through oral route in capsule form. The drug candidate is a triple reuptake inhibitor targeting norepinephrine, serotonin, and dopamine. It was also under development for the treatment of depression and major depressive disorder.
ConSynance Therapeutics overview
ConSynance Therapeutics, formerly Concerted Therapeutics is a drug discovery company that concentrates on the development of new therapeutic solutions for unmet medical needs. The company offers pipeline programs such as CSTI-100, CSTI-200, and CSTI-300, among others. It develops pipeline programs for nonalcoholic steatohepatitis and inflammatory bowel disease; type-2 diabetes and alzheimer’s disease, irritable bowel syndrome; and CNS diseases, among others. ConSynance Therapeutics offers several preclinical and early development programs in metabolic, autoimmune and digestive, among others. The company works in partnership with other pharma companies for drug development. ConSynance Therapeutics is headquartered in Rensselaer, New York, the US.
For a complete picture of CSTI-500’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
